[go: up one dir, main page]

AR042705A1 - Derivados de pirazol modulador de ppar - Google Patents

Derivados de pirazol modulador de ppar

Info

Publication number
AR042705A1
AR042705A1 ARP040100011A ARP040100011A AR042705A1 AR 042705 A1 AR042705 A1 AR 042705A1 AR P040100011 A ARP040100011 A AR P040100011A AR P040100011 A ARP040100011 A AR P040100011A AR 042705 A1 AR042705 A1 AR 042705A1
Authority
AR
Argentina
Prior art keywords
pirazol
derivatives
ppar modulator
methyl
ppar
Prior art date
Application number
ARP040100011A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR042705A1 publication Critical patent/AR042705A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a un compuesto, ácido {2-metil-4-[3-metil-1-(4-trifluorometilfenil)-1H-pirazol-4-ilmetilsulfanil]fenoxi}acético. Composiciones farmacéuticas aceptables del mismo, procesos de obtención, y su uso en el tratamiento de diabetes, entre otras enfermedades.
ARP040100011A 2003-01-06 2004-01-05 Derivados de pirazol modulador de ppar AR042705A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43856303P 2003-01-06 2003-01-06

Publications (1)

Publication Number Publication Date
AR042705A1 true AR042705A1 (es) 2005-06-29

Family

ID=32713346

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100011A AR042705A1 (es) 2003-01-06 2004-01-05 Derivados de pirazol modulador de ppar

Country Status (8)

Country Link
US (2) US20060241157A1 (es)
EP (2) EP1585733A1 (es)
AR (1) AR042705A1 (es)
AU (2) AU2003296404A1 (es)
CL (1) CL2004000011A1 (es)
PE (1) PE20041039A1 (es)
TW (1) TW200505867A (es)
WO (2) WO2004063165A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003296404A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heterocyclic ppar modulators
WO2004099156A1 (en) 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
WO2005105754A1 (en) * 2004-04-28 2005-11-10 F. Hoffmann-La Roche Ag Pyrazole phenyl derivatives as ppar activators
EP1745003B1 (en) 2004-05-05 2010-10-27 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
JP4981662B2 (ja) 2004-05-05 2012-07-25 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規の化合物、その製法と使用
FR2882359A1 (fr) * 2005-02-24 2006-08-25 Negma Lerads Soc Par Actions S Derives activateurs de ppar, procede de preparation et application en therapeutique
CN101166720A (zh) * 2005-02-28 2008-04-23 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
JPWO2006126514A1 (ja) 2005-05-27 2008-12-25 塩野義製薬株式会社 イソキサゾール骨格を有するアリール酢酸誘導体
WO2007002559A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
RU2412935C2 (ru) 2005-06-30 2011-02-27 Хай Пойнт Фармасьютикалс, ЛЛС Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar
US8097610B2 (en) 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
BRPI0615948A2 (pt) * 2005-09-07 2011-05-31 Plexxikon Inc composto ativo de ppar, sua composição, seu kit e seu uso
EA201101084A1 (ru) 2005-12-22 2012-04-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
KR101507173B1 (ko) 2006-04-18 2015-03-30 닛뽕 케미파 가부시키가이샤 페록시좀 증식제 활성화 수용체 δ 의 활성화제
JPWO2008010511A1 (ja) * 2006-07-19 2009-12-17 武田薬品工業株式会社 スクリーニング方法
US7998995B2 (en) 2006-12-08 2011-08-16 Exelixis Patent Company Llc LXR and FXR modulators
US20100183696A1 (en) * 2007-01-30 2010-07-22 Allergan, Inc Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists
KR20090129406A (ko) * 2007-02-23 2009-12-16 일라이 릴리 앤드 캄파니 퍼옥시좀 증식체 활성화 수용체 조절자
US8263630B2 (en) * 2008-02-12 2012-09-11 Bristol-Myers Squibb Company 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8648208B2 (en) 2008-04-15 2014-02-11 Nippon Chemiphar Co. Ltd. Activating agent for peroxisome proliferator activated receptor
CN101643451B (zh) 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
KR101898610B1 (ko) 2010-08-31 2018-09-14 서울대학교산학협력단 ＰＰＡＲδ 활성물질의 태자 재프로그래밍 용도
ES2568979T3 (es) * 2012-05-14 2016-05-05 Bayer Cropscience Ag Procedimiento de preparación de cloruros de ácido 1-alquil-3-fluoroalquil-1H-pirazol-4-carboxílico
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
KR102319577B1 (ko) 2014-01-24 2021-10-29 바이엘 크롭사이언스 악티엔게젤샤프트 １-알킬-３-디플루오로메틸-５-플루오르-１ｈ-피라졸-４-카르브알데히드 및 １-알킬-３-디플루오로메틸-５-플루오르-１ｈ-피라졸-４-카르복실레이트의 제조 방법
WO2018067860A1 (en) 2016-10-05 2018-04-12 Mitobridge, Inc. Crystalline and salt forms of ppar agonist compounds
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0442448A3 (en) * 1990-02-13 1992-08-12 Bristol-Myers Squibb Company Heterocyclic carboxylic acids and esters
JP3694774B2 (ja) 1997-10-31 2005-09-14 大鵬薬品工業株式会社 フェニルカルボン酸誘導体
DE60005973T2 (de) * 1999-08-27 2004-05-13 Eli Lilly And Co., Indianapolis Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
AR035912A1 (es) * 2000-03-02 2004-07-28 Aventis Cropscience Sa Compuestos de 4-tiometilpirazol, composicion plaguicida, metodo para el control de plagas en un lugar, semillas tratadas o recubiertas,uso de estos compuestos o composiciones para el control de plagas, uso de estos compuestos para preparar un medicamento veterinario, y,proceso para la preparacion de
EA200400011A1 (ru) * 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
WO2003099793A1 (en) * 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
AU2003296404A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heterocyclic ppar modulators

Also Published As

Publication number Publication date
TW200505867A (en) 2005-02-16
CL2004000011A1 (es) 2005-04-15
WO2004063166A1 (en) 2004-07-29
WO2004063166A8 (en) 2005-03-03
EP1583746A1 (en) 2005-10-12
US7396850B2 (en) 2008-07-08
WO2004063165A1 (en) 2004-07-29
AU2003296404A1 (en) 2004-08-10
EP1585733A1 (en) 2005-10-19
US20070043220A1 (en) 2007-02-22
AU2003296401A1 (en) 2004-08-10
PE20041039A1 (es) 2004-12-30
US20060241157A1 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
AR042705A1 (es) Derivados de pirazol modulador de ppar
GT200400239A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
UY27878A1 (es) Derivados de indolinfenilsulfonamida
EA200802208A1 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
WO2009124266A3 (en) Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
CY1108992T1 (el) Η χρηση του υαλουρονικου οξεος για την παρασκευη συνθεσεων για τη θεραπευτικη αντιμετωπιση υποτροπιαζουσων αφθων της στοματικης κοιλοτητας
EA200970726A1 (ru) Твердый препарат, содержащий алоглиптин и пиоглитазон
GT200500363A (es) 3-amino-pirazol [3,4b] piridinas con inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento.
WO2005097135A3 (en) Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
NO20071798L (no) Dermalt pafore formuleringer for behandling av hudsykdommer i dyr
ECSP088569A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y uso de los mismos para el tratamiento de enfermedades cardiovasculares
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
BRPI0519443A2 (pt) composto orgÂnicos
EA200401319A1 (ru) Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
UY28115A1 (es) Derivados del acido isoftalico
ATE460940T1 (de) Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen
RU2008147216A (ru) Жидкая лекарственная композиция
SE0400708D0 (sv) New compounds and use thereof
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
UY29065A1 (es) Derivados del ácido alcanoico arilcicloalquil-sustituidos, procedimientos para su preparación y su uso como productos farmacéuticos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure